drugset / Trial / NCT05282069
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder for 12 weeks as double-blind, placebo-controlled and active-reference study, and also will evaluate the long-term safety of DA-8010 for 52 weeks in patients with overactive bladder as open-label study.
Timeline
- Start
- 2022-05-12
- Primary completion
- 2023-11-01
- Completion
- 2024-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Solifenacin | Small molecule | 5 mg | Oral |
| Subject | VELUFENACIN | Small molecule | 2.5 mg | Oral |
| Subject | VELUFENACIN | Small molecule | 5 mg | Oral |